Introduction: This study explored the nature of the association between intraoperative usage of red blood cell, fresh frozen plasma, cryoprecipitate or platelet transfusions and acute kidney injury. Methods: A total of 1175 patients who underwent cardiac surgery between 2008 and 2013 were retrospectively analyzed. We assessed the association between: (1) preoperative patient characteristics and acute kidney injury, (2) intraoperative blood product usage and acute kidney injury, (3) acute kidney injury and 30-day mortality or re-hospitalization. Results: In our cohort of 1175 patients, 288 patients (24.5%) developed acute kidney injury. This included 162 (13.8%), 69 (5.9%) and 57 (4.9%) developing stage 1, stage 2 or stage 3 acute kidney injury, respectively. Increased red blood cell, fresh frozen plasma or platelet transfusions increased the odds of developing acute kidney injury. Specifically, every unit of red blood cells, fresh frozen plasma or platelets transfused was associated with an increase in the covariate-adjusted odds ratio of developing ⩾ stage 2 kidney injury of 1.18, 1.19 and 1.04, respectively. Conclusions: Intraoperative blood product transfusions were independently associated with an increased odds of developing acute kidney injury following cardiac surgery. Further randomized studies are needed to better define intraoperative transfusion criteria.
Introduction
Depending on the criteria used, the incidence of cardiac surgery-associated acute kidney injury (CSA-AKI) in adults is estimated to be up to 30%. 1, 2 This severe postoperative complication is associated with increased mortality, morbidity, intensive care unit stay, infections, readmission and hospital costs. [3] [4] [5] It is imperative to have effective strategies for reducing the incidence of CSA-AKI.
Various studies have identified preoperative and intraoperative risk factors for CSA-AKI. [6] [7] [8] [9] [10] While most of these risk factors are not modifiable, several studies have explored risk factors that are directly amendable to change, including: preoperative anemia, cardiopulmonary bypass (CPB) time, hemodilution during CPB, timing of cardiac catheterization and transfusions. [11] [12] [13] [14] Despite this research, trends in cardiac surgery from 1999 to 2008 reveal a tripling of CSA-AKI rates. 15 Intraoperative packed red blood cell (RBC) transfusion, a modifiable risk factor, has been independently associated with developing CSA-AKI as measured by postoperative serum creatinine (SCr) and kidney injury biomarkers. 11, 16, 17 Blood products used in cardiac surgery include: RBCs, fresh frozen plasma (FFP), cryoprecipitate, platelets and factor VIIa. The specific type of blood product transfused and the implications on kidney function have not been well elucidated. It is important to investigate the type of blood products used as different blood product transfusions have been associated with different outcomes following cardiac surgery. Specifically, RBC and platelet transfusions were found to be associated with an increased and decreased risk of infection, respectively. 18 Thus, it remains unknown as to whether certain blood products may yield adverse outcomes or are protective in terms of developing CSA-AKI.
We performed a retrospective analysis utilizing the STS database at a single institution (NIH Heart Center at Suburban Hospital, Bethesda, MD) to investigate the association between intraoperative blood product usage and AKI. We also assessed the association between preoperative demographic and clinical characteristics and AKI as well as the association between AKI and 30-day mortality or re-hospitalization. Of note, a key component of this study was to define AKI stages using the widely accepted Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines.
Methods

Study cohort
Waiver exemption for patient consent was obtained for this study and all personal health information was deidentified. A total of 1279 consecutive patients underwent cardiac surgery at our institution between January 2008 and June 2013 and were entered into the STS Adult Cardiac Surgery database. Patients were excluded from this study based on: emergent cases (n = 55), preoperative requirement for dialysis or renal failure defined as SCr ⩾4 mg/dL (n = 18) or incomplete SCr or transfusion data (n=31). Data from the remaining 1175 patients were analyzed. Patient demographics, risk factors and outcomes were retrospectively reviewed.
Institutional practices
Certain institutional practices, such as volume expansion, delay of catheterization and use of renin-angiotensin-altering medications, can affect outcomes. 12 In our institution, volume is administered as necessary based on physiologic requirements to maintain a mean arterial pressure greater than 60 mmHg and a cardiac index greater than 2.2 L/min/m 2 . The intraoperative transfusion trigger for RBC was a hemoglobin of 8.0 g/ dL or less if symptomatic; for FFP, a prothrombin time greater than 2 times normal or a partial thromboplastin time greater than 60 seconds; and for platelets, transfusion was employed for counts less than 50,000/microL. Glucose management was maintained by intravenous insulin drips for the first 24-48 hours to keep blood glucose levels less than 150 mg/dL. The interval between cardiac catheterization and surgery was dictated by clinical need and no policy to delay surgery for patients with normal renal function pre-catheterization was employed.
Dependent variable
The three stages of AKI were defined based on the KDIGO criteria: increase ⩾1.5 to 1.9 times the preoperative SCr (Stage 1); increase ⩾2 to 2.9 times the preoperative SCr (Stage 2); increase ⩾3 times the preoperative SCr, postoperative SCr at ⩾4.0mg/dL (354 μmol/L) or commencement of renal replacement therapy (Stage 3). The highest SCr measurement during hospital stay was used. Table 1 lists the preoperative and intraoperative variables we considered, based on past literature, to be potentially associated with AKI. We considered intraoperative blood product transfusion units (RBC, FFP, cryoprecipitate and platelets) as specific independent variables of interest.
Independent variables
Statistical analysis
The association between the various preoperative characteristics and AKI stage was assessed by the Chi-square statistic if the characteristic was categorical and by analysis of variance (ANOVA) if the characteristic was continuous. The association between postoperative complications and AKI stage was assessed using Fisher's Exact Test due to the small table cell numbers. Binary logistic regression was used to calculate the respective odds ratios (OR) of the AKI stages per unit of intraoperative blood product used. Adjusted ORs were calculated using variables from Table 1 that were previously shown in the literature to be associated with developing AKI and are listed in the Figure 1 legend. Binary logistic regression was used to calculate the ORs of post-surgery 30-day mortality, based on the AKI stage, with no AKI serving as the reference category. Due to the relatively few number of deaths (n = 43), the adjusted ORs for the mortality analyses only included the variables that had a p-value of <0.2 in an initial fit of all of the pre-specified clinically important adjustment variables. Since the adjusted ORs for mortality were essentially unchanged using the smaller set of adjustment variables, the adjusted ORs reported were based on the smaller set of variables. We similarly calculated the OR of postsurgery 30-day mortality or hospital readmission. Restricted cubic splines were used to plot the probability of ⩾stage 2 AKI as a function of the number of transfused intraoperative RBC, FFP and platelet units, respectively. Statistical analyses were performed using R 
Results
A total of 1175 patients were included in the study. In this patient cohort, 288 (24.5%) patients developed AKI, which included 162 (13.8%), 69 (5.9%) and 57 (4.9%) patients with stage 1, stage 2 or stage 3 AKI, respectively. Patient characteristics, stratified by AKI stage, are reported in Table 1 along with comparisons across stages using ANOVA or Chi-squared analysis.
Age, preoperative hematocrit and preoperative creatinine were most highly associated with AKI stage. Table  2 reports the complications following surgery. Stroke, septicemia, dialysis and mortality were highly associated with AKI stage.
The distributions of patients receiving different blood product transfusions and total number of transfusions are presented in Table 3 . Very few patients (<2%) received cryoprecipitate while RBC was the most frequent blood product used. Figure 1 reports the unadjusted and adjusted ORs of AKI stage per unit of RBC, FFP, cryoprecipitate or platelets transfused. Higher usage of RBC, FFP and platelets was associated with increased odds of AKI. There was no association between cryoprecipitate usage and AKI, which may have been due to the few patients receiving that specific product. Spline curve transformations were used to graph the unadjusted probability of developing stage 2 or greater AKI, based on the number of units of RBC, FFP and platelets given (Figure 2 ). The spline curve for RBC transfusions shows a nearly 20% probability for developing ⩾stage 2 AKI when 3 units were transfused.
The spline curve for FFP shows an approximately 20% probability of ⩾stage 2 AKI when 5 units of FFP were transfused. The unadjusted and adjusted ORs for mortality and the composite endpoint of mortality plus 30-day hospital Variables for which adjustments were made include: age, history of arrhythmia, coronary artery disease, diabetes, dyslipidemia, gender, NYHA class, hypertension, smoking; prior CV intervention, myocardial infarction; preoperative creatinine, hematocrit; preoperative use of ACE or ARB, heparin, Coumadin, or antiplatelets; type of surgery (CABG, valvular, both); crossclamp time, urgent surgical status (yes/no), weight.
readmission are shown in Figure 3 . These odds ratios are with respect to AKI stage, using no AKI as the reference category.
Discussion
In this study, CSA-AKI occurred in 288 (24.8%) of 1175 patients undergoing elective or urgent cardiac surgery. The rate of AKI was similar to that of other studies that used AKI Network (AKIN) or Risk/Injury/ Failure/Loss/End-stage (RIFLE) criteria for the diagnosis of AKI. 19 Demographic and clinical characteristics that differed between stages of AKI in univariate analysis (p<0.05) included: age, history of diabetes, hypertension, New York Heart Association (NYHA) Functional Classification, preoperative use of heparin, preoperative hematocrit, preoperative creatinine, preor postoperative use of an intra-aortic balloon pump, aortic aneurysm surgery and cross-clamp time (Table  1 ). These variables have been previously shown to be associated with AKI. 8, 11 In the patients studied, complications differed across the stages of AKI (Table 2) . Reoperation for bleeding, stroke, septicemia, dialysis and mortality were most prevalent in patients who developed stage 3 AKI. Using no AKI as the reference category, unadjusted and adjusted ORs for mortality were not statistically significant for stage 1 AKI, but were significant (p<0.0001) for patients who developed stage 2 or 3 AKI ( Figure 3A ). There was a stepwise increase in the probability of mortality with escalating AKI severity -adjusted odds of patient death quintupled when considering patients who developed stage 2 (OR 9.6, 95% CI 3.1-29.6) versus stage 3 AKI (OR 52.2, 95% CI 20-136). The odds of the composite endpoint of readmission or mortality also increased with increasing AKI stage ( Figure 3B) . Similar results were shown in a previous study evaluating mortality after cardiac surgery and the association with escalating AKI stage based on KDIGO criteria. 20 Presumably, in patients with stage 2 and 3 AKI, the resultant metabolic derangement and need for dialysis account for the increased mortality. Prior studies have shown that even a minimum increase in SCr is associated with adverse outcomes, including mortality and readmission. 21, 22 However, when adjusting for patient and procedural risk factors in our study cohort, mortality and readmission were only associated with the more severe stages of AKI.
Intraoperative RBC transfusions have been independently linked to developing CSA-AKI by several studies. 4, 11, 16, 17, 21 A meta-analysis showed that each unit of perioperative RBC transfusion is independently associated with a 10-20% increased risk of developing CSA-AKI. 17 However, the studies considered in the meta-analysis did not have a unifying definition of AKI and many did not control for preoperative anemia, a potential confounding factor. The pathophysiologic mechanisms involved in transfusion-related AKI are not completely understood. Based on experimental evidence, it is believed that RBC transfusions in conjunction with CPB promote a pro-inflammatory state, decrease tissue oxygen delivery (potentially leading to tissue hypoxia) and aggravate tissue oxidative stress through increased hemolysis of transfused RBCs and, subsequently, amplified levels of free hemoglobin and iron. [23] [24] [25] In his review, Karkouti provides compelling evidence that the observed association between transfusion and CSA-AKI is likely causal. 16 Although, the pathophysiology of this association is not completely understood, Karkouti substantiates several of the nine proposed characteristics specific to the Hill criteria for interpreting the nature of an association as cause and effect.
The association between other blood product transfusions, including platelets, FFP and cryoprecipitate, with CSA-AKI has not been thoroughly characterized. A recent prospective study showed a protective association between platelet transfusions and infection following cardiac surgery. 18 In our study, an independent association existed between intraoperative RBC transfusions and CSA-AKI ( Figure 1B) , with an adjusted OR = 1.18 (95% CI 1.10-1.27) for ⩾stage 2 AKI per RBC unit transfused. These results matched a recent metaanalysis showing 10-20% increased risk of developing CSA-AKI per intraoperative RBC unit transfused. 15 The spline curve for RBC transfusions shows a steep slope from 1-4 units, with a nearly 20% probability of developing ⩾stage 2 AKI when 3 units were transfused (Figure 2A) . Similarly, there was an adjusted OR = 1.19 (95% CI 1.09-1.30) of ⩾stage 2 AKI per FFP unit transfused. The spline curve for FFP showed a similar relationship to RBC although the initial slope was not as steep, with an approximately 20% probability of ⩾stage 2 AKI when 5 units of FFP were transfused. There was an adjusted OR = 1.04 (95% CI 1.01-1.07) of ⩾stage 2 per platelet unit transfused. As seen from the spline curve, the relationship between platelets and AKI, although statistically significant, is more gradual than RBC or FFP transfusions. Finally, there was no significant association between cryoprecipitate transfused and AKI. This may have been due to fewer than 2% of the patients receiving cryoprecipitate ( Table 3) .
The results from this study confirm the well-known independent association of RBC transfusions and the development of AKI, but also provide novel data revealing an association between FFP and platelet transfusion with the development of CSA-AKI. A potential mechanism for RBC transfusions causing AKI has been delineated. 16, [23] [24] [25] How FFP and platelet transfusions may lead or contribute to CSA-AKI is not understood. Investigations on potential mechanisms responsible for the development of AKI following FFP and platelet transfusions are needed.
Due to the challenging nature of designing a trial aimed at randomizing patients to a transfusion or no transfusion arm, only randomized trials looking at restrictive versus liberal transfusion triggers have been studied in cardiac surgery. A recent randomized trial showed that a restrictive transfusion trigger postoperatively was not superior in regards to morbidity (including kidney injury) to a liberal transfusion trigger in patients after cardiac surgery. 26 This was in contrast to observational studies showing a clear benefit with more restrictive transfusion triggers. A metaanalysis of randomized trials looking at restrictive or liberal transfusion triggers in cardiac surgery supported the finding that a restrictive transfusion strategy is non-superior to a liberal transfusion plan in regards to mortality, which showed a disparity between the data pooled in observational studies. 27 However, this meta-analysis had several shortcomings, including: differing restrictive and liberal transfusion strategies among the trials studied, heterogeneity in evaluating trials that included postoperative or intraoperative transfusions, varying levels of non-adherence to the predefined transfusion triggers and the unavailability of mortality data in one of the trials analyzed. The Transfusion Requirements in Cardiac Surgery III Trial is currently ongoing and should provide more definitive data on the utility of using a restrictive versus liberal transfusion trigger in both the intraoperative and postoperative cardiac surgery setting.
An important limitation of our study is that all of the data was from a single center, which potentially limits the generalizability of the results. In contradistinction, it is a "real-world" report that captured all patients over several years. In this study, we may have underestimated the number of stage 1 AKI patients as the KDIGO Criteria state that ⩾0.3mg/dL change in SCr within 48 hours or 1.5x increase in baseline SCr equates to stage 1 AKI, but the coding for the STS database inputs the highest postoperative value for SCr. Therefore, we only used the 1.5x increase in baseline SCr as the criterion for developing stage I AKI and some patients may have been missed. However, a study investigating the RIFLE (defining AKI as 1.5x increase in baseline SCr) and AKIN (defining AKI as 0.3 mg/dL change in SCr within 48 hours) criteria found little difference in the incidence of AKI and prediction of mortality between the two classification guidelines. 28 In conclusion, this study used the KDIGO criteria to investigate the possible association between intraoperative RBC, FFP, cryoprecipitate and platelet transfusions with AKI. Greater usage of intraoperative RBC, FFP and platelet transfusions were each found to be independently associated with CSA-AKI. Future studies are needed to understand whether causality exists between transfusion and AKI along with the need to evaluate the impact of reducing intraoperative blood product usage on patient outcomes.
